Principles for characterizing the potential human health effects from exposure to nanomaterials

Elements of a screening strategy

Günter Oberdörster, Andrew Maynard, Ken Donaldson, Vincent Castranova, Julie Fitzpatrick, Kevin Ausman, Janet Carter, Barbara Karn, Wolfgang Kreyling, David Lai, Stephen Olin, Nancy Monteiro-Riviere, David Warheit, Hong Yang

Research output: Contribution to journalArticle

1431 Citations (Scopus)

Abstract

The rapid proliferation of many different engineered nanomaterials (defined as materials designed and produced to have structural features with at least one dimension of 100 nanometers or less) presents a dilemma to regulators regarding hazard identification. The International Life Sciences Institute Research Foundation/Risk Science Institute convened an expert working group to develop a screening strategy for the hazard identification of engineered nanomaterials. The working group report presents the elements of a screening strategy rather than a detailed testing protocol. Based on an evaluation of the limited data currently available, the report presents a broad data gathering strategy applicable to this early stage in the development of a risk assessment process for nanomaterials. Oral, dermal, inhalation, and injection routes of exposure are included recognizing that, depencting on use patterns, exposure to nanomaterials may occur by any of these routes. The three key elements of the toxicity screening strategy are: Physicochemical Characteristics, In Vitro Assays (cellular and non-cellular), and In Vivo Assays. There is a strong likelihood that biological activity of nanoparticles will depend on physicochemical parameters not routinely considered in toxicity screening studies. Physicochemical properties that may be important in understanding the toxic effects of test materials include particle size and size distribution, agglomeration state, shape, crystal structure, chemical composition, surface area, surface chemistry, surface charge, and porosity. In vitro techniques allow specific biological and mechanistic pathways to be isolated and tested under controlled conditions, in ways that are not feasible in in vivo tests. Tests are suggested for portal-of-entry toxicity for lungs, skin, and the mucosal membranes, and target organ toxicity for endothelium, blood, spleen, liver, nervous system, heart, and kidney. Non-cellular assessment of nanoparticle durability, protein interactions, complement activation, and pro-oxidant activity is also considered. Tier I in vivo assays are proposed for pulmonary, oral, skin and injection exposures, and Tier 2 evaluations for pulmonary exposures are also proposed. Tier I evaluations include markers of inflammation, oxidant stress, and cell proliferation in portal-of-entry and selected remote organs and tissues. Tier 2 evaluations for pulmonary exposures could include deposition, translocation, and toxicokinetics and biopersistence studies; effects of multiple exposures; potential effects on the reproductive system, placenta, and fetus; alternative animal models; and mechanistic studies.

Original languageEnglish (US)
Article number8
JournalParticle and Fibre Toxicology
Volume2
DOIs
StatePublished - Oct 6 2005
Externally publishedYes

Fingerprint

Nanostructures
Nanostructured materials
Toxicity
Screening
Health
Assays
Lung
Nanoparticles
Skin
Hazards
Injections
Biological Science Disciplines
Complement Activation
Poisons
Porosity
Cell proliferation
Neurology
Surface charge
Bioactivity
Surface chemistry

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Principles for characterizing the potential human health effects from exposure to nanomaterials : Elements of a screening strategy. / Oberdörster, Günter; Maynard, Andrew; Donaldson, Ken; Castranova, Vincent; Fitzpatrick, Julie; Ausman, Kevin; Carter, Janet; Karn, Barbara; Kreyling, Wolfgang; Lai, David; Olin, Stephen; Monteiro-Riviere, Nancy; Warheit, David; Yang, Hong.

In: Particle and Fibre Toxicology, Vol. 2, 8, 06.10.2005.

Research output: Contribution to journalArticle

Oberdörster, G, Maynard, A, Donaldson, K, Castranova, V, Fitzpatrick, J, Ausman, K, Carter, J, Karn, B, Kreyling, W, Lai, D, Olin, S, Monteiro-Riviere, N, Warheit, D & Yang, H 2005, 'Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy', Particle and Fibre Toxicology, vol. 2, 8. https://doi.org/10.1186/1743-8977-2-8
Oberdörster, Günter ; Maynard, Andrew ; Donaldson, Ken ; Castranova, Vincent ; Fitzpatrick, Julie ; Ausman, Kevin ; Carter, Janet ; Karn, Barbara ; Kreyling, Wolfgang ; Lai, David ; Olin, Stephen ; Monteiro-Riviere, Nancy ; Warheit, David ; Yang, Hong. / Principles for characterizing the potential human health effects from exposure to nanomaterials : Elements of a screening strategy. In: Particle and Fibre Toxicology. 2005 ; Vol. 2.
@article{e9e113e24d3d43bd8f93f55cdb98bb59,
title = "Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy",
abstract = "The rapid proliferation of many different engineered nanomaterials (defined as materials designed and produced to have structural features with at least one dimension of 100 nanometers or less) presents a dilemma to regulators regarding hazard identification. The International Life Sciences Institute Research Foundation/Risk Science Institute convened an expert working group to develop a screening strategy for the hazard identification of engineered nanomaterials. The working group report presents the elements of a screening strategy rather than a detailed testing protocol. Based on an evaluation of the limited data currently available, the report presents a broad data gathering strategy applicable to this early stage in the development of a risk assessment process for nanomaterials. Oral, dermal, inhalation, and injection routes of exposure are included recognizing that, depencting on use patterns, exposure to nanomaterials may occur by any of these routes. The three key elements of the toxicity screening strategy are: Physicochemical Characteristics, In Vitro Assays (cellular and non-cellular), and In Vivo Assays. There is a strong likelihood that biological activity of nanoparticles will depend on physicochemical parameters not routinely considered in toxicity screening studies. Physicochemical properties that may be important in understanding the toxic effects of test materials include particle size and size distribution, agglomeration state, shape, crystal structure, chemical composition, surface area, surface chemistry, surface charge, and porosity. In vitro techniques allow specific biological and mechanistic pathways to be isolated and tested under controlled conditions, in ways that are not feasible in in vivo tests. Tests are suggested for portal-of-entry toxicity for lungs, skin, and the mucosal membranes, and target organ toxicity for endothelium, blood, spleen, liver, nervous system, heart, and kidney. Non-cellular assessment of nanoparticle durability, protein interactions, complement activation, and pro-oxidant activity is also considered. Tier I in vivo assays are proposed for pulmonary, oral, skin and injection exposures, and Tier 2 evaluations for pulmonary exposures are also proposed. Tier I evaluations include markers of inflammation, oxidant stress, and cell proliferation in portal-of-entry and selected remote organs and tissues. Tier 2 evaluations for pulmonary exposures could include deposition, translocation, and toxicokinetics and biopersistence studies; effects of multiple exposures; potential effects on the reproductive system, placenta, and fetus; alternative animal models; and mechanistic studies.",
author = "G{\"u}nter Oberd{\"o}rster and Andrew Maynard and Ken Donaldson and Vincent Castranova and Julie Fitzpatrick and Kevin Ausman and Janet Carter and Barbara Karn and Wolfgang Kreyling and David Lai and Stephen Olin and Nancy Monteiro-Riviere and David Warheit and Hong Yang",
year = "2005",
month = "10",
day = "6",
doi = "10.1186/1743-8977-2-8",
language = "English (US)",
volume = "2",
journal = "Particle and Fibre Toxicology",
issn = "1743-8977",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Principles for characterizing the potential human health effects from exposure to nanomaterials

T2 - Elements of a screening strategy

AU - Oberdörster, Günter

AU - Maynard, Andrew

AU - Donaldson, Ken

AU - Castranova, Vincent

AU - Fitzpatrick, Julie

AU - Ausman, Kevin

AU - Carter, Janet

AU - Karn, Barbara

AU - Kreyling, Wolfgang

AU - Lai, David

AU - Olin, Stephen

AU - Monteiro-Riviere, Nancy

AU - Warheit, David

AU - Yang, Hong

PY - 2005/10/6

Y1 - 2005/10/6

N2 - The rapid proliferation of many different engineered nanomaterials (defined as materials designed and produced to have structural features with at least one dimension of 100 nanometers or less) presents a dilemma to regulators regarding hazard identification. The International Life Sciences Institute Research Foundation/Risk Science Institute convened an expert working group to develop a screening strategy for the hazard identification of engineered nanomaterials. The working group report presents the elements of a screening strategy rather than a detailed testing protocol. Based on an evaluation of the limited data currently available, the report presents a broad data gathering strategy applicable to this early stage in the development of a risk assessment process for nanomaterials. Oral, dermal, inhalation, and injection routes of exposure are included recognizing that, depencting on use patterns, exposure to nanomaterials may occur by any of these routes. The three key elements of the toxicity screening strategy are: Physicochemical Characteristics, In Vitro Assays (cellular and non-cellular), and In Vivo Assays. There is a strong likelihood that biological activity of nanoparticles will depend on physicochemical parameters not routinely considered in toxicity screening studies. Physicochemical properties that may be important in understanding the toxic effects of test materials include particle size and size distribution, agglomeration state, shape, crystal structure, chemical composition, surface area, surface chemistry, surface charge, and porosity. In vitro techniques allow specific biological and mechanistic pathways to be isolated and tested under controlled conditions, in ways that are not feasible in in vivo tests. Tests are suggested for portal-of-entry toxicity for lungs, skin, and the mucosal membranes, and target organ toxicity for endothelium, blood, spleen, liver, nervous system, heart, and kidney. Non-cellular assessment of nanoparticle durability, protein interactions, complement activation, and pro-oxidant activity is also considered. Tier I in vivo assays are proposed for pulmonary, oral, skin and injection exposures, and Tier 2 evaluations for pulmonary exposures are also proposed. Tier I evaluations include markers of inflammation, oxidant stress, and cell proliferation in portal-of-entry and selected remote organs and tissues. Tier 2 evaluations for pulmonary exposures could include deposition, translocation, and toxicokinetics and biopersistence studies; effects of multiple exposures; potential effects on the reproductive system, placenta, and fetus; alternative animal models; and mechanistic studies.

AB - The rapid proliferation of many different engineered nanomaterials (defined as materials designed and produced to have structural features with at least one dimension of 100 nanometers or less) presents a dilemma to regulators regarding hazard identification. The International Life Sciences Institute Research Foundation/Risk Science Institute convened an expert working group to develop a screening strategy for the hazard identification of engineered nanomaterials. The working group report presents the elements of a screening strategy rather than a detailed testing protocol. Based on an evaluation of the limited data currently available, the report presents a broad data gathering strategy applicable to this early stage in the development of a risk assessment process for nanomaterials. Oral, dermal, inhalation, and injection routes of exposure are included recognizing that, depencting on use patterns, exposure to nanomaterials may occur by any of these routes. The three key elements of the toxicity screening strategy are: Physicochemical Characteristics, In Vitro Assays (cellular and non-cellular), and In Vivo Assays. There is a strong likelihood that biological activity of nanoparticles will depend on physicochemical parameters not routinely considered in toxicity screening studies. Physicochemical properties that may be important in understanding the toxic effects of test materials include particle size and size distribution, agglomeration state, shape, crystal structure, chemical composition, surface area, surface chemistry, surface charge, and porosity. In vitro techniques allow specific biological and mechanistic pathways to be isolated and tested under controlled conditions, in ways that are not feasible in in vivo tests. Tests are suggested for portal-of-entry toxicity for lungs, skin, and the mucosal membranes, and target organ toxicity for endothelium, blood, spleen, liver, nervous system, heart, and kidney. Non-cellular assessment of nanoparticle durability, protein interactions, complement activation, and pro-oxidant activity is also considered. Tier I in vivo assays are proposed for pulmonary, oral, skin and injection exposures, and Tier 2 evaluations for pulmonary exposures are also proposed. Tier I evaluations include markers of inflammation, oxidant stress, and cell proliferation in portal-of-entry and selected remote organs and tissues. Tier 2 evaluations for pulmonary exposures could include deposition, translocation, and toxicokinetics and biopersistence studies; effects of multiple exposures; potential effects on the reproductive system, placenta, and fetus; alternative animal models; and mechanistic studies.

UR - http://www.scopus.com/inward/record.url?scp=33845214358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845214358&partnerID=8YFLogxK

U2 - 10.1186/1743-8977-2-8

DO - 10.1186/1743-8977-2-8

M3 - Article

VL - 2

JO - Particle and Fibre Toxicology

JF - Particle and Fibre Toxicology

SN - 1743-8977

M1 - 8

ER -